Compare ProShares Ultra QQQ ETF (QLD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? ProShares Ultra QQQ ETF trades at $90.05 (market cap $15.24B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: ProShares Ultra QQQ ETF is far larger — about 3.1× Travere Therapeutics Inc. Common Stock's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QLD | TVTX | |
|---|---|---|
Market Cap | $15.24B | $4.88B |
Volume | 2,898,706 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $67.52 |
52-Week Low | $57.16 | $26.79 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $96.42, down 0.68% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, positioning it as a less volatile alternative to triple-leveraged products during market downturns. Recent institutional buying by 180 Wealth Advisors LLC increased their position by 29.4% in Q2 2026, signaling confidence in the fund's strategy.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $95-$97 and resistance at $98-$99. While leveraged ETFs offer amplified returns, they carry elevated risk from daily rebalancing and market volatility. Investors should monitor Fed policy impacts and tech sector momentum for directional cues, with the current setup favoring tactical positions above key support levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
